SLC5A2 and type 2 diabetes mellitus: 51 Zelniker Zelniker TA TA Wiviott Wiviott SD SD Raz Raz I I SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes a systematic review and meta-analysis of cardiovascular outcome trials SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes a systematic review and meta-analysis of cardiovascular outcome trials Lancet Lancet 2019 2019 393 393 31 31 39 39 30424892 30424892